person · Reporting owner
Hill Christopher Scott
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORE LABORATORIES N VCLB · Entity 11862 | SVP & CFO | February 16, 2023 | February 21, 2023 |
| Core Laboratories Inc. /DE/CLB · Entity 5382 | SVP & CFO | February 12, 2026 | February 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORE LABORATORIES N V
Report date February 16, 2023 · Filed February 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 52,718 |
Reported balance
After 2023-02-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-16 · Grant · Acquired 52,718 · Balance 52,718 F1: This award vests at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F2: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. |
Filing footnotes · ownership attribution and instrument terms
F1: This award vests at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, at the end of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital (ROIC) among the Bloomberg Peer Group (BPG), 100% of the award will vest if the Company is in the top 55th percentile of ROIC of the BPG, and 175% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period.
F2: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period.
Core Laboratories Inc. /DE/
Report date February 12, 2026 · Filed February 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 70,008 |
Reported balance
After 2026-02-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-12 · Grant · Acquired 70,008 · Balance 70,008 F2: This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital ("ROIC") among the Bloomberg Peer Group ("BPG"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. F3: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile of ROIC (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile of ROIC (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period. |
| Common StockSEC Table I · non-derivative | Indirect401(k) Plan | 59 |
Reported balance
Holding disclosure · report date 2026-02-12 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 59 F1: The Reporting Person's indirect beneficial ownership includes 59 shares of the Issuer's common stock held in the Issuer's 401(k) plan, which were previously reported but were inadvertently omitted from a prior Form 4 filing. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person's indirect beneficial ownership includes 59 shares of the Issuer's common stock held in the Issuer's 401(k) plan, which were previously reported but were inadvertently omitted from a prior Form 4 filing.
F2: This award vests following the conclusion of a three-year performance period that began on January 1, 2026 and ends on December 31, 2028 (the "Performance Period"). This award survives termination of employment due to death, disability, termination by the Company without cause or retirement by the employee upon having reached 62 years of age. In all cases, the shares will vest, if at all, on December 31, 2028, following the conclusion of the Performance Period as follows: 50% of the award will vest if the Company is in the top 35th percentile of Return on Invested Capital ("ROIC") among the Bloomberg Peer Group ("BPG"), 100% of the award will vest if the Company is in the top 55th percentile of ROIC among the BPG, and 175% of the award will vest if the Company is at or above the 85th percentile of ROIC among the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period.
F3: The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 35th and 55th percentile of ROIC (equivalent to 50% up to 100% of the award) and again between the 55th and 85th percentile of ROIC (equivalent to 100% up to 175% of the award). The number of common shares that could vest over 100% of the award up to the maximum of 175% of the award, if any, will be reduced by one-half if absolute total shareholder return for the Performance Period is negative, as measured and determined by the Compensation Committee at the end of the Performance Period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2018 Filed Mar 9, 2018 18:33 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-18-000039 · wf-form4_152063842416905.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 18:00 UTC | CORE LABORATORIES N V CLB · Entity 11862 | GrantPerformance Shares · Derivative | 2,600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-18-000035 · wf-form4_151873562535853.xml · derivative · entry 1 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600 Underlying: Common Shares · 2,600 shares Expires not disclosed F1 · derivative.exercise_date: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance goals is achieved, these awards would vest at the end of a three-year performance period that begins on January 1, 2018 and ends on the last NYSE trading day of December 2020 (the "Performance Period"). At the end of the Performance Period, 100% of the award will vest if the Company is in the top 75th percentile of Return On Invested Capital of the Bloomberg Peer Group as shown by data published by Bloomberg upon the close of the NYSE market on the last trading day of the Performance Period. If this criteria is not met, then no shares shall vest and the award be forfeited. F1 · derivative.expiration_date: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance goals is achieved, these awards would vest at the end of a three-year performance period that begins on January 1, 2018 and ends on the last NYSE trading day of December 2020 (the "Performance Period"). At the end of the Performance Period, 100% of the award will vest if the Company is in the top 75th percentile of Return On Invested Capital of the Bloomberg Peer Group as shown by data published by Bloomberg upon the close of the NYSE market on the last trading day of the Performance Period. If this criteria is not met, then no shares shall vest and the award be forfeited. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 18:08 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionPerformance Shares · Derivative | 3,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-18-000015 · wf-form4_151502091107612.xml · derivative · entry 4 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares vesting were awarded as restricted performance shares in May 2015. As reported in the Form 4 filing on May 7, 2015 at the time the award was made, "The restricted performance shares will vest only upon the Company's return on invested capital being in the top decile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period and the shares shall fully vest if that criterion is met. If it is not met, then no shares shall vest and the award shall be forfeited." The performance criteria and all requirements for vesting have been met and thus the shares fully vested on December 29, 2017, at the conclusion of the performance period. F1 · derivative.expiration_date: The shares vesting were awarded as restricted performance shares in May 2015. As reported in the Form 4 filing on May 7, 2015 at the time the award was made, "The restricted performance shares will vest only upon the Company's return on invested capital being in the top decile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period and the shares shall fully vest if that criterion is met. If it is not met, then no shares shall vest and the award shall be forfeited." The performance criteria and all requirements for vesting have been met and thus the shares fully vested on December 29, 2017, at the conclusion of the performance period. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 18:08 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 821 | $109.55 | $89,940.55 |
DisclosureSEC source: 0001000229-18-000015 · wf-form4_151502091107612.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,540 Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 18:08 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-18-000015 · wf-form4_151502091107612.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 17:53 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-17-000095 · wf-form4_151251441879968.xml · derivative · entry 4 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484 Underlying: Common Shares · 125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · derivative.exercise_date: Multiple restricted share grants are included in this total. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · derivative.expiration_date: Multiple restricted share grants are included in this total. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 17:53 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 35 | $105.04 | $3,676.40 |
DisclosureSEC source: 0001000229-17-000095 · wf-form4_151251441879968.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,361 Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 17:53 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 125 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-17-000095 · wf-form4_151251441879968.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 16:08 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-17-000081 · wf-form4_150464209821732.xml · derivative · entry 4 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 609 Underlying: Common Shares · 125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · derivative.exercise_date: Multiple restricted share grants are included in this total. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · derivative.expiration_date: Multiple restricted share grants are included in this total. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 16:08 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 35 | $89.59 | $3,135.65 |
DisclosureSEC source: 0001000229-17-000081 · wf-form4_150464209821732.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,271 Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 16:08 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 125 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-17-000081 · wf-form4_150464209821732.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2017 Filed Apr 5, 2017 09:06 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 53 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-17-000054 · wf-form4_149139759858098.xml · derivative · entry 4 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 734 Underlying: Common Shares · 53 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. Read SEC document |
| April 01, 2017 Filed Apr 5, 2017 09:06 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 18 | $115.52 | $2,079.36 |
DisclosureSEC source: 0001000229-17-000054 · wf-form4_149139759858098.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,181 Read SEC document |
| April 01, 2017 Filed Apr 5, 2017 09:06 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 53 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-17-000054 · wf-form4_149139759858098.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:54 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 100 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-17-000038 · wf-form4_148857808127037.xml · derivative · entry 4 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 787 Underlying: Common Shares · 100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · derivative.exercise_date: Multiple restricted share grants are included in this total. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · derivative.expiration_date: Multiple restricted share grants are included in this total. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:54 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 33 | $118.74 | $3,918.42 |
DisclosureSEC source: 0001000229-17-000038 · wf-form4_148857808127037.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,146 Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:54 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-17-000038 · wf-form4_148857808127037.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 16:56 UTC | CORE LABORATORIES N V CLB · Entity 11862 | GrantRestricted Performance Shares · Derivative | 2,400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-17-000031 · wf-form4_148728217063569.xml · derivative · entry 1 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 Underlying: Common Shares · 2,400 shares Expires not disclosed F1 · derivative.exercise_date: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance goals is achieved, these awards would vest at the end of a three-year performance period that began on January 1, 2017 and ends on the last NYSE trading day of December 2019 (the "Performance Period"). At the end of the Performance Period, these restricted performance shares will vest only if the Company's return on invested capital (ROIC) is in the top 75th percentile of the Bloomberg Peer Group as shown by data published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period. If that criterion is met, the awards shall fully vest and if that criterion is not met, then no shares shall vest and the award shall be forfeited. F1 · derivative.expiration_date: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance goals is achieved, these awards would vest at the end of a three-year performance period that began on January 1, 2017 and ends on the last NYSE trading day of December 2019 (the "Performance Period"). At the end of the Performance Period, these restricted performance shares will vest only if the Company's return on invested capital (ROIC) is in the top 75th percentile of the Bloomberg Peer Group as shown by data published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period. If that criterion is met, the awards shall fully vest and if that criterion is not met, then no shares shall vest and the award shall be forfeited. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 16:05 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-16-000224 · wf-form4_148097190098868.xml · derivative · entry 4 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887 Underlying: Common Shares · 125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · balance_after: Multiple restricted share grants are included in this total. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 16:05 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 35 | $116.14 | $4,064.90 |
DisclosureSEC source: 0001000229-16-000224 · wf-form4_148097190098868.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,079 Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 16:05 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 125 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-16-000224 · wf-form4_148097190098868.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2016 Filed Oct 3, 2016 16:18 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 150 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001000229-16-000211 · wf-form4_147552591785854.xml · derivative · entry 4 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,012 Underlying: Common Shares · 150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · balance_after: Multiple restricted share grants are included in this total. Read SEC document |
| October 01, 2016 Filed Oct 3, 2016 16:18 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 42 | $112.33 | $4,717.86 |
DisclosureSEC source: 0001000229-16-000211 · wf-form4_147552591785854.xml · nonDerivative · entry 2 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,989 Read SEC document |
| October 01, 2016 Filed Oct 3, 2016 16:18 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 150 | $0.00 | $0.00 |
DisclosureSEC source: 0001000229-16-000211 · wf-form4_147552591785854.xml · nonDerivative · entry 1 Hill Christopher Scott · CIK 0001641315 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.